バイオマニュファクチャリング市場 - 世界の産業規模、シェア、動向、機会、予測：ワークフロー別、用途別、エンドユーザー別、地域別、競合、2020年～2030年

バイオマニュファクチャリングの世界市場規模は2024年に190億8,000万米ドルに達し、2030年までの予測期間中にCAGRで7.72%の目覚ましい成長が予測されています。

バイオマニュファクチャリング市場は、バイオテクノロジーおよび製薬業界における重要なセグメントであり、生物学的由来製品の大規模生産に焦点を当てています。これには、モノクローナル抗体、治療用タンパク質、細胞・遺伝子治療薬、ワクチン、その他従来の化学合成では製造できない複雑な生物学的製品などのバイオ医薬品が含まれます。バイオマニュファクチャリングには、細胞培養、発酵、精製、品質管理など、さまざまな高度なプロセスが含まれ、高度に制御された環境と高度なバイオリアクターシステムを必要とすることが多いです。この市場は、世界中の患者が救命や生命増強のための治療薬を確実に利用できるようにする上で、極めて重要な役割を果たしています。個別化医療に対する需要の増加、慢性疾患の有病率の上昇、遺伝子工学の急速な進歩に後押しされ、バイオマニュファクチャリング部門は大幅な成長を遂げています。

例えば、WHOによれば、糖尿病患者数は1990年の2億人から2022年には8億3,000万人に増加します。この増加は、高所得国に比べて低・中所得国で著しく速く、世界の健康課題の増大と発展途上地域における的を絞った予防・管理戦略の必要性を浮き彫りにしています。シングルユース技術、自動化、連続バイオプロセシングなどの革新は、生産能力を変革し、効率を高め、コストを削減しています。生物学的製剤のパイプラインの拡大とバイオシミラーの出現は、市場に新たな機会を生み出しています。規制当局もまた、迅速な承認と製造の柔軟性をサポートするために適応しています。科学研究が進歩し続ける中、バイオマニュファクチャリング市場は、次世代治療薬の迅速な開発を可能にし、世界のヘルスケアの課題に取り組む上でますます不可欠な存在となる構えです。

市場促進要因

先端技術と新機軸の採用

主な市場課題

巨額の資本支出

主要市場動向

連続的バイオマニュファクチャリングの出現

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のバイオマニュファクチャリング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • ワークフロー別（アップストリームの連続、アップストリームのシングルユース、ダウンストリーム）
  • 用途別（モノクローナル抗体、ホルモン、ワクチン、組換えタンパク質、その他）
  • エンドユーザー別（バイオ医薬品企業、研究機関、CMO/CDMO）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のバイオマニュファクチャリング市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のバイオマニュファクチャリング市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のバイオマニュファクチャリング市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のバイオマニュファクチャリング市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのバイオマニュファクチャリング市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Illumina Inc.
• Thermo Fischer Scientific Inc.
• Oxford Nanopore Technologies plc
• Agilent Technologies, Inc.
• BGI Genomics Co. Ltd.
• PerkinElmer Inc.
• QIAGEN NV
• Eurofins Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Takara Bio Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Bio-Manufacturing Market has valued at USD 19.08 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.72% through 2030. The biomanufacturing market is a vital segment within the biotechnology and pharmaceutical industry, focusing on the large-scale production of biologically derived products. These include biopharmaceuticals such as monoclonal antibodies, therapeutic proteins, cell and gene therapies, vaccines, and other complex biological products that cannot be produced through traditional chemical synthesis. Biomanufacturing involves a range of sophisticated processes, including cell culture, fermentation, purification, and quality control, often requiring highly controlled environments and advanced bioreactor systems. This market plays a crucial role in ensuring the availability of life-saving and life-enhancing therapies for patients across the globe. Driven by increasing demand for personalized medicine, rising prevalence of chronic diseases, and rapid advances in genetic engineering, the biomanufacturing sector is experiencing substantial growth.

For instance, according to WHO, the number of people living with diabetes increased from 200 million in 1990 to 830 million in 2022. The rise has been significantly faster in low- and middle-income countries compared to high-income nations, highlighting a growing global health challenge and the need for targeted prevention and management strategies in developing regions. Innovations such as single-use technologies, automation, and continuous bioprocessing are transforming production capabilities, enhancing efficiency, and reducing costs. The expanding pipeline of biologic drugs and the emergence of biosimilars are creating new opportunities within the market. Regulatory agencies are also adapting to support accelerated approvals and manufacturing flexibility. As scientific research continues to advance, the biomanufacturing market is poised to become increasingly essential in addressing global healthcare challenges, enabling faster development and distribution of next-generation therapies.

Key Market Drivers

Adoption of Advanced Technology and New Innovation

The rise in the geriatric population and the prevalence of chronic respiratory disorders are anticipated to drive the demand for ventilators. Increasing awareness of lung cancer symptoms and a growing number of patients in medical facilities contribute to the significant market growth of ventilators. For instance, in November 2023, the FDA approved Ixchiq, the first vaccine for chikungunya, for adults aged 18 and older. In December 2023, the FDA approved Casgevy and Lyfgenia-the first cell-based gene therapies-for treating sickle cell disease in patients aged 12 and older, marking major milestones in infectious disease prevention and genetic disorder treatment. However, it should be noted that the use of mechanical ventilation may pose certain risks, such as increased infection risk and potential damage to the lungs. These considerations should be taken into account when assessing the market growth potential of Bio-Manufacturing. Advanced technologies such as automation, robotics, and process control systems can streamline biomanufacturing processes, reduce human error, and enhance overall production efficiency. This can lead to quicker turnaround times and increased production capacity, meeting the growing demand for biologics. Innovative bioreactor designs, single-use technologies, and flexible manufacturing platforms allow for easier scalability of production. As demand for bio manufactured products grows, the ability to quickly scale up production will become essential. Continuous manufacturing approaches, as opposed to traditional batch processes, can lead to consistent product quality, reduced wastage, and improved resource utilization. These advantages can boost demand for bio manufactured products.

Key Market Challenges

Huge Capital Expenditure

The biomanufacturing process involves intricate and specialized equipment, facilities, and technologies, which can require significant financial investments. Setting up a biomanufacturing facility or upgrading existing infrastructure requires substantial initial capital investment. This includes the construction or renovation of specialized cleanrooms, purchase of bioreactors, purification equipment, and other sophisticated tools necessary for biopharmaceutical production. The substantial capital required for biomanufacturing can divert resources away from other critical areas such as research and development, marketing, and business expansion. This resource allocation challenge can impact a company's overall growth strategy. The high capital expenditure can result in overestimation or underutilization of manufacturing capacity. If demand for the manufactured product is lower than anticipated, the investment may not yield the expected returns.

Key Market Trends

Emergence of Continuous Biomanufacturing

The emergence of continuous biomanufacturing has the potential to significantly boost the growth of the biomanufacturing industry in the future. Continuous biomanufacturing represents a departure from traditional batch processes by enabling the seamless, uninterrupted production of biopharmaceuticals and other biologically derived products. This innovative approach offers several benefits that can positively impact efficiency, flexibility, cost-effectiveness, and overall market expansion. Continuous biomanufacturing allows for continuous monitoring and adjustment of process parameters in real-time. This leads to improved process control, reduced variability, and enhanced product consistency, resulting in higher process efficiency and reduced production times. Continuous biomanufacturing systems are generally more compact and require less physical space than traditional batch systems. This reduction in facility footprint can lead to cost savings and greater flexibility in facility design and location. Continuous biomanufacturing can enable higher production capacities by running processes continuously, thereby increasing output without the need for significant facility expansion. This increased capacity can meet the growing demand for biopharmaceuticals and other biologically derived products.

Key Market Players

Illumina Inc.

Thermo Fischer Scientific Inc.

Oxford Nanopore Technologies plc

Agilent Technologies, Inc.

BGI Genomics Co. Ltd.

PerkinElmer Inc.

QIAGEN NV

Eurofins Scientific Inc.

F. Hoffmann-La Roche Ltd

Takara Bio Inc.

Report Scope:

In this report, the Global Bio-Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bio-Manufacturing Market, By Workflow:

• Continuous Upstream Biomanufacturing
• Single-Use Upstream Biomanufacturing
• Downstream Biomanufacturing

Bio-Manufacturing Market, By Application:

• Monoclonal Antibodies
• Hormones
• Vaccines
• Recombinant Proteins
• Others

Bio-Manufacturing Market, By End User:

• Biopharmaceutical Companies
• Research Institutions
• CMOs/CDMOs

Bio-Manufacturing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bio-Manufacturing Market.

Available Customizations:

Global Bio-Manufacturing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bio-Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Workflow (Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, Downstream Biomanufacturing)
  • 5.2.2. By Application (Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, Others)
  • 5.2.3. By End User (Biopharmaceutical Companies, Research Institutions, CMOs/CDMOs)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Bio-Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Workflow
  • 6.2.2. By Application
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bio-Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Workflow
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada Bio-Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Workflow
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico Bio-Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Workflow
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End Use

7. Europe Bio-Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Workflow
  • 7.2.2. By Application
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bio-Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Workflow
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End Use
  • 7.3.2. United Kingdom Bio-Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Workflow
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End Use
  • 7.3.3. Italy Bio-Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Workflow
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End Use
  • 7.3.4. France Bio-Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Workflow
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Bio-Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Workflow
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End Use

8. Asia-Pacific Bio-Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Workflow
  • 8.2.2. By Application
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Bio-Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Workflow
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Bio-Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Workflow
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan Bio-Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Workflow
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea Bio-Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Workflow
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Bio-Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Workflow
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End Use

9. South America Bio-Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Workflow
  • 9.2.2. By Application
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Bio-Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Workflow
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End Use
  • 9.3.2. Argentina Bio-Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Workflow
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End Use
  • 9.3.3. Colombia Bio-Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Workflow
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End Use

10. Middle East and Africa Bio-Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Workflow
  • 10.2.2. By Application
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Bio-Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Workflow
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End Use
  • 10.3.2. Saudi Arabia Bio-Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Workflow
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End Use
  • 10.3.3. UAE Bio-Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Workflow
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Illumina Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Thermo Fischer Scientific Inc.
• 14.3. Oxford Nanopore Technologies plc
• 14.4. Agilent Technologies, Inc.
• 14.5. BGI Genomics Co. Ltd.
• 14.6. PerkinElmer Inc.
• 14.7. QIAGEN NV
• 14.8. Eurofins Scientific Inc.
• 14.9. F. Hoffmann-La Roche Ltd
• 14.10. Takara Bio Inc.

15. Strategic Recommendations

16. About Us & Disclaimer